STOCKS CLIMB BUT MICRON SLIDES, WITH DATA IN FOCUS

U.S. economic growth for last quarter revised up slightly to 1.4% annual rate

SRPT Nov 2024 185.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

10.00

0.00

(0.00%)

As of 03:36PM EDT. Market open.

Loading interactive chart...

GuruFocus.com
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
Ryan Brown, EVP, General Counsel of Sarepta Therapeutics Inc (NASDAQ:SRPT), sold 38,957 shares of the company on June 25, 2024.
Investor's Business Daily
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.
Zacks
Company News for Jun 24, 2024
Companies In The News Are: FDS, SRPT, HTZ, ASAN.